Michael Becker to Gout
This is a "connection" page, showing publications Michael Becker has written about Gout.
Connection Strength
9.912
-
Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study). Arthritis Rheumatol. 2017 01; 69(1):203-212.
Score: 0.537
-
Summary of the 2015 Purine and Pyrimidine Society/Purine Metabolic Patients Association H. Anne Simmonds Memorial Lecture. Nucleosides Nucleotides Nucleic Acids. 2016 Dec; 35(10-12):502-506.
Score: 0.534
-
An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015 Oct; 45(2):174-83.
Score: 0.480
-
Urate transporters: transforming the face of hyperuricemia and gout. J Rheumatol. 2014 Oct; 41(10):1910-2.
Score: 0.457
-
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014 Mar 04; 16(2):R60.
Score: 0.442
-
Long-term management of gout: nonpharmacologic and pharmacologic therapies. Rheum Dis Clin North Am. 2014 May; 40(2):357-74.
Score: 0.440
-
Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab. 2013 Nov; 15(11):1049-55.
Score: 0.420
-
Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013 Sep 01; 72(9):1469-74.
Score: 0.403
-
Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides Nucleotides Nucleic Acids. 2011 Dec; 30(12):1011-7.
Score: 0.378
-
Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011; 14(1):10-5.
Score: 0.353
-
What do I need to know about gout? J Fam Pract. 2010 Jun; 59(6 Suppl):S1-8.
Score: 0.340
-
Quality of life and disability in patients with treatment-failure gout. J Rheumatol. 2009 May; 36(5):1041-8.
Score: 0.314
-
Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009 Jun; 36(6):1273-82.
Score: 0.313
-
Update on emerging urate-lowering therapies. Curr Opin Rheumatol. 2009 Mar; 21(2):143-9.
Score: 0.312
-
Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008 Jun; 27(6):585-91.
Score: 0.296
-
We can make gout management more successful now. Curr Opin Rheumatol. 2008 Mar; 20(2):167-72.
Score: 0.291
-
Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005 Dec 08; 353(23):2450-61.
Score: 0.249
-
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005 Mar; 52(3):916-23.
Score: 0.236
-
Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004 Aug; 31(8):1575-81.
Score: 0.227
-
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. Arthritis Rheumatol. 2022 09; 74(9):1593-1601.
Score: 0.198
-
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. Arthritis Rheumatol. 2019 01; 71(1):143-153.
Score: 0.154
-
Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Arthritis Res Ther. 2018 05 30; 20(1):99.
Score: 0.148
-
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018 Mar 29; 378(13):1200-1210.
Score: 0.146
-
Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment. Arthritis Rheumatol. 2016 08; 68(8):2035-43.
Score: 0.130
-
Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease. Curr Med Res Opin. 2015; 31 Suppl 2:9-14.
Score: 0.117
-
Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol. 2014 Dec; 20(8):427-32.
Score: 0.116
-
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013 Sep 26; 15(5):R137.
Score: 0.107
-
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012 Feb; 64(2):256-61.
Score: 0.096
-
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011 Aug 17; 306(7):711-20.
Score: 0.093
-
Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol. 2011 Jul; 38(7):1452-7.
Score: 0.092
-
Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities. J Rheumatol. 2011 Jul; 38(7):1458-61.
Score: 0.092
-
Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology? J Rheumatol. 2011 Jul; 38(7):1462-6.
Score: 0.092
-
Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials. J Rheumatol. 2011 Jul; 38(7):1467-70.
Score: 0.092
-
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12(2):R63.
Score: 0.084
-
Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009 Feb; 48(2):188-94.
Score: 0.078
-
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008 Nov 15; 59(11):1540-8.
Score: 0.076
-
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008 Sep; 58(9):2882-91.
Score: 0.075
-
Inherited superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid overproduction and sensorineural deafness. Am J Med. 1988 Sep; 85(3):383-90.
Score: 0.075
-
Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout). Rheum Dis Clin North Am. 1988 Aug; 14(2):377-94.
Score: 0.075
-
A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Ann Rheum Dis. 2008 Jun; 67(6):888-91.
Score: 0.072
-
Outcome evaluations in gout. J Rheumatol. 2007 Jun; 34(6):1381-5.
Score: 0.069
-
Magnetic resonance imaging in the quantitative assessment of gouty tophi. Int J Clin Pract. 2006 Apr; 60(4):408-14.
Score: 0.064
-
Tophaceous gout: quantitative evaluation by direct physical measurement. J Rheumatol. 2005 Dec; 32(12):2368-72.
Score: 0.062
-
Outcome measures for acute and chronic gout. J Rheumatol. 2005 Dec; 32(12):2452-5.
Score: 0.062
-
Diagnostic evaluation of phosphoribosylpyrophosphate synthetase activities in hemolysates. J Lab Clin Med. 1984 Jun; 103(6):932-43.
Score: 0.056
-
Gout with superactive phosphoribosylpyrophosphate synthetase due to increased enzyme catalytic rate. J Lab Clin Med. 1982 Apr; 99(4):495-511.
Score: 0.048
-
Fibroblast phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in gout with purine overproduction. Adv Exp Med Biol. 1977; 76A:270-9.
Score: 0.034
-
Diminished affinity for purine substrates as a basis for gout with mild deficiency of hypoxanthine-guanine phosphoribosyltransferase. Adv Exp Med Biol. 1977; 76A:319-25.
Score: 0.034
-
Patterns of phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in fibroblasts from patients with gout and purine overproduction. J Clin Invest. 1976 Feb; 57(2):308-18.
Score: 0.032
-
Genetic aspects of gout. Annu Rev Med. 1974; 25(0):15-28.
Score: 0.027
-
Human phosphoribosylpyrophosphate synthetase: increased enzyme specific activity in a family with gout and excessive purine synthesis. Proc Natl Acad Sci U S A. 1973 Oct; 70(10):2749-52.
Score: 0.027
-
Gout with purine overproduction due to increased phosphoribosylpyrophosphate synthetase activity. Am J Med. 1973 Aug; 55(2):232-42.
Score: 0.026
-
Purine overproduction in man associated with increased phosphoribosylpyrophosphate synthetase activity. Science. 1973 Mar 16; 179(4078):1123-6.
Score: 0.026
-
Increased PP-ribose-P synthetase activity: a genetic abnormality leading to excessive purine production and gout. Adv Exp Med Biol. 1973; 41:307-15.
Score: 0.025
-
Identification of distinct PRS1 mutations in two patients with X-linked phosphoribosylpyrophosphate synthetase superactivity. Adv Exp Med Biol. 1991; 309B:125-8.
Score: 0.022
-
Rheumatology. JAMA. 1989 May 19; 261(19):2887-8.
Score: 0.020
-
Neurodevelopmental impairment and deranged PRPP and purine nucleotide synthesis in inherited superactivity of PRPP synthetase. Adv Exp Med Biol. 1989; 253A:15-22.
Score: 0.019
-
Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman. Arthritis Rheum. 2003 Jul; 48(7):2036-41.
Score: 0.013
-
Recent advances in the identification of enzyme abnormalities underlying excessive purine synthesis in man. Arthritis Rheum. 1975 Nov-Dec; 18(6 Suppl):687-94.
Score: 0.008
-
Evaluation of the role of 5-phosphoribosyl-alpha-1-pyrophosphate synthetase in congenital hyperuricemia and gout: a simple isotopic assay and an activity stain for the enzyme. Biochem Med. 1974 Jul; 10(3):266-75.
Score: 0.007